Bio­gen, Seagen lock in CEOs; 2022 so far — by the num­bers; Phar­ma on Twit­ter; Wave of biotech down­siz­ing ; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Drew Arm­strong has of­fi­cial­ly joined the End­points team. We are thrilled to wel­come him and ex­cit­ed for his new vi­sion. If you have any feed­back or thoughts, don’t hes­i­tate to reach out. You can re­ply to this email to reach an ed­i­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER